Navigation Links
A Broad-Spectrum Antibiotic with Activity Against MRSA and Pseudomonas Aeruginosa Would Earn a Higher Patient Share in the U.S. than in Europe for the Treatment of Hospital-Acquired Pneumonia
Date:3/3/2009

Merck's Drug Will Remain Decision Resources Gold Standard Through 2017, According to a New Report from Decision Resources

WALTHAM, Mass., March 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a broad-spectrum intravenous antibiotic that has activity against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), shows higher efficacy than the current benchmark (Wyeth's Zosyn/Tazocin) and is priced 50 percent higher than Zosyn/Tazocin would earn a higher patient share in the U.S. (50 percent) than in Europe (30 percent) for the treatment of hospital-acquired pneumonia. This is due to infectious disease specialists in Europe being more sensitive to pricing in their prescribing decisions.

The new report entitled Hospital-Acquired Pneumonia: Resistance Concerns Create Opportunities for New Broad-Spectrum Antibiotics also finds that Merck's Primaxin will remain Decision Resources' proprietary clinical gold standard through 2017. While some therapies in development for hospital-acquired pneumonia hold promise, most have efficacy, safety and tolerability and/or delivery issues when compared to Primaxin.

"Interviewed thought leaders believe that Primaxin has a better spectrum of activity than the benchmark therapy, Zosyn/Tazocin and perceive the agent to be more active against ESBL-producing E. coli and Klebsiella pneumoniae, Pseudomonas and Acinetobacter," stated Hemali Patel, Ph.D., analyst at Decision Resources. "Prescribers we surveyed agree that Primaxin is the most effective antibiotic for hospital-acquired pneumonia."

About the Report

Hospital-Acquired Pneumonia: Resistance Concerns Create Opportunities for New Broad-Spectrum Antibiotics is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Antibiotic Combo Fights Resistant TB
2. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
3. Antibiotic-Resistant Meningitis Reported in U.S.
4. Health experts urge supermarket pharmacies to get smart about free antibiotics
5. Activity Against Drug-Resistant Pathogens is One of the Leading Attributes Influencing Physicians Antibiotic Selection for the Treatment of Inpatient Community-Acquired Pneumonia
6. Could carbon dioxide replace antibiotics in surgery?
7. Study shows rise in antibiotic resistant pediatric head and neck infections
8. Free antibiotics: The wrong prescription for cold and flu season
9. E. coli persists against antibiotics through HipA-induced dormancy
10. Antibiotics as Loss Leaders?
11. Preventive Use of Antibiotics Cuts ICU Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing ... the product – with nearly 2,000 consumers (and counting) already backing the campaign. ...
(Date:3/24/2017)... ... ... Viewers who like to educate themselves on current issues and who enjoy gaining ... issues tend to appreciate and love the "Informed" series, hosted by Rob Lowe. ... causes around the world. , Running for charity has become a multi-million ...
(Date:3/24/2017)... ... 24, 2017 , ... “End Time GPS”: a dauntless and enlightened study ... Time GPS” is the creation of published author, Wesley Gerboth, a World War II ... and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon ...
(Date:3/23/2017)... ... ... A recent report from the National Council on Teacher Quality (NCTQ) advocates for ... on a review of GPA and SAT/ACT requirements at 221 institutions in 25 states, ... that this higher bar should be set by states, by the Council for the ...
(Date:3/23/2017)... MN (PRWEB) , ... March 23, 2017 , ... The ... internet and WiFi connectivity are making a huge impact on businesses and individual consumers ... Institute estimates the IoT will have a value anywhere from $4 trillion to $11 ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... FinancialBuzz.com News Commentary   ... Medical cannabis products around the world are projected to ... global medical cannabis market will reach a value of USD 55.8 billion ... for the new growing industry. By the end of 2016, 28 states ... medical cannabis. More conservative states like Arkansas and ...
(Date:3/24/2017)... March 24, 2017 Global Ampoules ... including definitions, classifications, applications and industry chain structure. The ... including development history, competitive landscape analysis, and major regions, ... ... across 105 pages providing 10 company profiles and 183 ...
(Date:3/24/2017)... March 24, 2017  Eli Lilly and Company ... to invest $850 million in its U.S. operations ... its U.S. enterprise, including research laboratories, manufacturing sites, ... being driven by demand for Lilly products, as ... in development targeting cancer, pain, diabetes and other ...
Breaking Medicine Technology: